Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 152

1.

A randomized, double-blind, phase 2 study of ruxolitinib or placebo in combination with capecitabine in patients with advanced HER2-negative breast cancer and elevated C-reactive protein, a marker of systemic inflammation.

O'Shaughnessy J, DeMichele A, Ma CX, Richards P, Yardley DA, Wright GS, Kalinsky K, Steis R, Diab S, Kennealey G, Geschwindt R, Jiang W, Rugo HS.

Breast Cancer Res Treat. 2018 Apr 19. doi: 10.1007/s10549-018-4770-6. [Epub ahead of print]

PMID:
29675680
2.

Neoadjuvant Chemotherapy Considerations in Triple-Negative Breast Cancer.

McAndrew N, DeMichele A.

J Target Ther Cancer. 2018 Feb;7(1):52-69. Epub 2018 Feb 14.

3.

Clinical Cancer Advances 2018: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology.

Heymach J, Krilov L, Alberg A, Baxter N, Chang SM, Corcoran R, Dale W, DeMichele A, Magid Diefenbach CS, Dreicer R, Epstein AS, Gillison ML, Graham DL, Jones J, Ko AH, Lopez AM, Maki RG, Rodriguez-Galindo C, Schilsky RL, Sznol M, Westin SN, Burstein H.

J Clin Oncol. 2018 Apr 1;36(10):1020-1044. doi: 10.1200/JCO.2017.77.0446. Epub 2018 Jan 30.

PMID:
29380678
4.

Clinical considerations of the role of palbociclib in the management of advanced breast cancer patients with and without visceral metastases.

Turner NC, Finn RS, Martin M, Im SA, DeMichele A, Ettl J, Diéras V, Moulder S, Lipatov O, Colleoni M, Cristofanilli M, Lu DR, Mori A, Giorgetti C, Iyer S, Bartlett CH, Gelmon KA.

Ann Oncol. 2018 Mar 1;29(3):669-680. doi: 10.1093/annonc/mdx797.

5.

Mechanisms of Resistance to Neoadjuvant Chemotherapy in Breast Cancer.

DeMichele A, Yee D, Esserman L.

N Engl J Med. 2017 Dec 7;377(23):2287-2289. doi: 10.1056/NEJMcibr1711545. No abstract available.

PMID:
29211674
6.

Aurora A Functional Single Nucleotide Polymorphism (SNP) Correlates With Clinical Outcome in Patients With Advanced Solid Tumors Treated With Alisertib, an Investigational Aurora A Kinase Inhibitor.

Niu H, Shin H, Gao F, Zhang J, Bahamon B, Danaee H, Melichar B, Schilder RJ, Coleman RL, Falchook G, Adenis A, Behbakht K, DeMichele A, Dees EC, Perez K, Matulonis U, Sawrycki P, Huebner D, Ecsedy J.

EBioMedicine. 2017 Nov;25:50-57. doi: 10.1016/j.ebiom.2017.10.015. Epub 2017 Oct 16.

7.

Safety and Efficacy of Intratumoral Injections of Chimeric Antigen Receptor (CAR) T Cells in Metastatic Breast Cancer.

Tchou J, Zhao Y, Levine BL, Zhang PJ, Davis MM, Melenhorst JJ, Kulikovskaya I, Brennan AL, Liu X, Lacey SF, Posey AD Jr, Williams AD, So A, Conejo-Garcia JR, Plesa G, Young RM, McGettigan S, Campbell J, Pierce RH, Matro JM, DeMichele AM, Clark AS, Cooper LJ, Schuchter LM, Vonderheide RH, June CH.

Cancer Immunol Res. 2017 Dec;5(12):1152-1161. doi: 10.1158/2326-6066.CIR-17-0189. Epub 2017 Nov 6.

PMID:
29109077
8.

DNA repair deficiency biomarkers and the 70-gene ultra-high risk signature as predictors of veliparib/carboplatin response in the I-SPY 2 breast cancer trial.

Wolf DM, Yau C, Sanil A, Glas A, Petricoin E, Wulfkuhle J, Severson TM, Linn S, Brown-Swigart L, Hirst G, Buxton M, DeMichele A, Hylton N, Symmans F, Yee D, Paoloni M, Esserman L, Berry D, Rugo H, Olopade O, van 't Veer L.

NPJ Breast Cancer. 2017 Aug 25;3:31. doi: 10.1038/s41523-017-0025-7. eCollection 2017.

9.

Strategic recruitment of an ethnically diverse cohort of overweight survivors of breast cancer with lymphedema.

Sturgeon KM, Hackley R, Fornash A, Dean LT, Laudermilk M, Brown JC, Sarwer DB, DeMichele AM, Troxel AB, Schmitz KH.

Cancer. 2018 Jan 1;124(1):95-104. doi: 10.1002/cncr.30935. Epub 2017 Sep 7.

PMID:
28881471
10.

University of Pennsylvania ninth annual conference on statistical issues in clinical trials: Where are we with adaptive clinical trial designs? (afternoon panel discussion).

Connor JT, DeMichele A, Wittes J.

Clin Trials. 2017 Oct;14(5):470-482. doi: 10.1177/1740774517723605. Epub 2017 Aug 4. No abstract available.

PMID:
28776417
11.

The women in steady exercise research (WISER) survivor trial: The innovative transdisciplinary design of a randomized controlled trial of exercise and weight-loss interventions among breast cancer survivors with lymphedema.

Winkels RM, Sturgeon KM, Kallan MJ, Dean LT, Zhang Z, Evangelisti M, Brown JC, Sarwer DB, Troxel AB, Denlinger C, Laudermilk M, Fornash A, DeMichele A, Chodosh LA, Schmitz KH.

Contemp Clin Trials. 2017 Oct;61:63-72. doi: 10.1016/j.cct.2017.07.017. Epub 2017 Jul 21.

12.

Adding Adjuvant Systemic Treatment after Neoadjuvant Therapy in Breast Cancer: Review of the Data.

Patel SA, DeMichele A.

Curr Oncol Rep. 2017 Aug;19(8):56. doi: 10.1007/s11912-017-0613-6. Review.

PMID:
28733827
13.

Exosome RNA Unshielding Couples Stromal Activation to Pattern Recognition Receptor Signaling in Cancer.

Nabet BY, Qiu Y, Shabason JE, Wu TJ, Yoon T, Kim BC, Benci JL, DeMichele AM, Tchou J, Marcotrigiano J, Minn AJ.

Cell. 2017 Jul 13;170(2):352-366.e13. doi: 10.1016/j.cell.2017.06.031.

PMID:
28709002
14.

Arginine-Nitric Oxide Metabolites and Cardiac Dysfunction in Patients With Breast Cancer.

Finkelman BS, Putt M, Wang T, Wang L, Narayan H, Domchek S, DeMichele A, Fox K, Matro J, Shah P, Clark A, Bradbury A, Narayan V, Carver JR, Tang WHW, Ky B.

J Am Coll Cardiol. 2017 Jul 11;70(2):152-162. doi: 10.1016/j.jacc.2017.05.019. Erratum in: J Am Coll Cardiol. 2017 Nov 28;70(21):2738.

PMID:
28683962
15.

Erratum to: Comparative clinical utility of tumor genomic testing and cell-free DNA in metastatic breast cancer.

Maxwell KN, Soucier-Ernst D, Tahirovic E, Troxel AB, Clark C, Feldman M, Colameco C, Kakrecha B, Langer M, Lieberman D, Morrissette JJD, Paul MR, Pan TC, Yee S, Shih N, Carpenter E, Chodosh LA, DeMichele A.

Breast Cancer Res Treat. 2017 Aug;164(3):639-640. doi: 10.1007/s10549-017-4339-9. No abstract available.

PMID:
28653249
16.

Standard and Genomic Tools for Decision Support in Breast Cancer Treatment.

Henry NL, Bedard PL, DeMichele A.

Am Soc Clin Oncol Educ Book. 2017;37:106-115. doi: 10.14694/EDBK_175617. Review.

17.

Comparative clinical utility of tumor genomic testing and cell-free DNA in metastatic breast cancer.

Maxwell KN, Soucier-Ernst D, Tahirovic E, Troxel AB, Clark C, Feldman M, Colameco C, Kakrecha B, Langer M, Lieberman D, Morrissette JJD, Paul MR, Pan TC, Yee S, Shih N, Carpenter E, Chodosh LA, DeMichele A.

Breast Cancer Res Treat. 2017 Aug;164(3):627-638. doi: 10.1007/s10549-017-4257-x. Epub 2017 May 12. Erratum in: Breast Cancer Res Treat. 2017 Jun 26;:.

PMID:
28500398
18.

Characterization of Neutropenia in Advanced Cancer Patients Following Palbociclib Treatment Using a Population Pharmacokinetic-Pharmacodynamic Modeling and Simulation Approach.

Sun W, O'Dwyer PJ, Finn RS, Ruiz-Garcia A, Shapiro GI, Schwartz GK, DeMichele A, Wang D.

J Clin Pharmacol. 2017 Sep;57(9):1159-1173. doi: 10.1002/jcph.902. Epub 2017 Apr 18.

PMID:
28419480
19.

Longitudinal optical monitoring of blood flow in breast tumors during neoadjuvant chemotherapy.

Cochran JM, Chung SH, Leproux A, Baker WB, Busch DR, DeMichele AM, Tchou J, Tromberg BJ, Yodh AG.

Phys Med Biol. 2017 Jun 21;62(12):4637-4653. doi: 10.1088/1361-6560/aa6cef. Epub 2017 Apr 12.

PMID:
28402286
20.

The use of a patient-reported outcome questionnaire to assess cancer survivorship concerns and psychosocial outcomes among recent survivors.

Palmer SC, Stricker CT, DeMichele AM, Schapira M, Glanz K, Griggs JJ, Jacobs LA.

Support Care Cancer. 2017 Aug;25(8):2405-2412. doi: 10.1007/s00520-017-3646-3. Epub 2017 Feb 23.

PMID:
28233121
21.

Genetic variants of age at menopause are not related to timing of ovarian failure in breast cancer survivors.

Homer MV, Charo LM, Natarajan L, Haunschild C, Chung K, Mao JJ, DeMichele AM, Su HI.

Menopause. 2017 Jun;24(6):663-668. doi: 10.1097/GME.0000000000000817.

PMID:
28118297
22.

Dendritic Cell Vaccination Enhances Immune Responses and Induces Regression of HER2pos DCIS Independent of Route: Results of Randomized Selection Design Trial.

Lowenfeld L, Mick R, Datta J, Xu S, Fitzpatrick E, Fisher CS, Fox KR, DeMichele A, Zhang PJ, Weinstein SP, Roses RE, Czerniecki BJ.

Clin Cancer Res. 2017 Jun 15;23(12):2961-2971. doi: 10.1158/1078-0432.CCR-16-1924. Epub 2016 Dec 13.

PMID:
27965306
23.

Anastrozole in Pulmonary Arterial Hypertension. A Randomized, Double-Blind, Placebo-controlled Trial.

Kawut SM, Archer-Chicko CL, DeMichele A, Fritz JS, Klinger JR, Ky B, Palevsky HI, Palmisciano AJ, Patel M, Pinder D, Propert KJ, Smith KA, Stanczyk F, Tracy R, Vaidya A, Whittenhall ME, Ventetuolo CE.

Am J Respir Crit Care Med. 2017 Feb 1;195(3):360-368. doi: 10.1164/rccm.201605-1024OC.

24.

A novel approach for next-generation sequencing of circulating tumor cells.

Yee SS, Lieberman DB, Blanchard T, Rader J, Zhao J, Troxel AB, DeSloover D, Fox AJ, Daber RD, Kakrecha B, Sukhadia S, Belka GK, DeMichele AM, Chodosh LA, Morrissette JJ, Carpenter EL.

Mol Genet Genomic Med. 2016 Feb 28;4(4):395-406. doi: 10.1002/mgg3.210. eCollection 2016 Jul.

25.

Adaptive Randomization of Veliparib-Carboplatin Treatment in Breast Cancer.

Rugo HS, Olopade OI, DeMichele A, Yau C, van 't Veer LJ, Buxton MB, Hogarth M, Hylton NM, Paoloni M, Perlmutter J, Symmans WF, Yee D, Chien AJ, Wallace AM, Kaplan HG, Boughey JC, Haddad TC, Albain KS, Liu MC, Isaacs C, Khan QJ, Lang JE, Viscusi RK, Pusztai L, Moulder SL, Chui SY, Kemmer KA, Elias AD, Edmiston KK, Euhus DM, Haley BB, Nanda R, Northfelt DW, Tripathy D, Wood WC, Ewing C, Schwab R, Lyandres J, Davis SE, Hirst GL, Sanil A, Berry DA, Esserman LJ; I-SPY 2 Investigators.

N Engl J Med. 2016 Jul 7;375(1):23-34. doi: 10.1056/NEJMoa1513749.

26.

Adaptive Randomization of Neratinib in Early Breast Cancer.

Park JW, Liu MC, Yee D, Yau C, van 't Veer LJ, Symmans WF, Paoloni M, Perlmutter J, Hylton NM, Hogarth M, DeMichele A, Buxton MB, Chien AJ, Wallace AM, Boughey JC, Haddad TC, Chui SY, Kemmer KA, Kaplan HG, Isaacs C, Nanda R, Tripathy D, Albain KS, Edmiston KK, Elias AD, Northfelt DW, Pusztai L, Moulder SL, Lang JE, Viscusi RK, Euhus DM, Haley BB, Khan QJ, Wood WC, Melisko M, Schwab R, Helsten T, Lyandres J, Davis SE, Hirst GL, Sanil A, Esserman LJ, Berry DA; I-SPY 2 Investigators.

N Engl J Med. 2016 Jul 7;375(1):11-22. doi: 10.1056/NEJMoa1513750.

27.

Palbociclib in Combination With Fulvestrant in Women With Hormone Receptor-Positive/HER2-Negative Advanced Metastatic Breast Cancer: Detailed Safety Analysis From a Multicenter, Randomized, Placebo-Controlled, Phase III Study (PALOMA-3).

Verma S, Bartlett CH, Schnell P, DeMichele AM, Loi S, Ro J, Colleoni M, Iwata H, Harbeck N, Cristofanilli M, Zhang K, Thiele A, Turner NC, Rugo HS.

Oncologist. 2016 Oct;21(10):1165-1175. Epub 2016 Jul 1.

28.

Addition of anti-estrogen therapy to anti-HER2 dendritic cell vaccination improves regional nodal immune response and pathologic complete response rate in patients with ERpos/HER2pos early breast cancer.

Lowenfeld L, Zaheer S, Oechsle C, Fracol M, Datta J, Xu S, Fitzpatrick E, Roses RE, Fisher CS, McDonald ES, Zhang PJ, DeMichele A, Mick R, Koski GK, Czerniecki BJ.

Oncoimmunology. 2016 Jul 1;6(9):e1207032. doi: 10.1080/2162402X.2016.1207032. eCollection 2017.

29.

A cross-sectional survey of pain catastrophising and acupuncture use among breast cancer survivors.

Lee I, Garland SN, DeMichele A, Farrar JT, Im EO, Mao JJ.

Acupunct Med. 2017 Mar;35(1):38-43. doi: 10.1136/acupmed-2016-011056. Epub 2016 May 13.

PMID:
27177930
30.

Noninvasive Measures of Ventricular-Arterial Coupling and Circumferential Strain Predict Cancer Therapeutics-Related Cardiac Dysfunction.

Narayan HK, French B, Khan AM, Plappert T, Hyman D, Bajulaiye A, Domchek S, DeMichele A, Clark A, Matro J, Bradbury A, Fox K, Carver JR, Ky B.

JACC Cardiovasc Imaging. 2016 Oct;9(10):1131-1141. doi: 10.1016/j.jcmg.2015.11.024. Epub 2016 Apr 13.

31.

Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial.

Cristofanilli M, Turner NC, Bondarenko I, Ro J, Im SA, Masuda N, Colleoni M, DeMichele A, Loi S, Verma S, Iwata H, Harbeck N, Zhang K, Theall KP, Jiang Y, Bartlett CH, Koehler M, Slamon D.

Lancet Oncol. 2016 Apr;17(4):425-439. doi: 10.1016/S1470-2045(15)00613-0. Epub 2016 Mar 3. Erratum in: Lancet Oncol. 2016 Apr;17 (4):e136. Erratum in: Lancet Oncol. 2016 Jul;17 (7):e270.

PMID:
26947331
32.

Self-renewal of CD133(hi) cells by IL6/Notch3 signalling regulates endocrine resistance in metastatic breast cancer.

Sansone P, Ceccarelli C, Berishaj M, Chang Q, Rajasekhar VK, Perna F, Bowman RL, Vidone M, Daly L, Nnoli J, Santini D, Taffurelli M, Shih NN, Feldman M, Mao JJ, Colameco C, Chen J, DeMichele A, Fabbri N, Healey JH, Cricca M, Gasparre G, Lyden D, Bonafé M, Bromberg J.

Nat Commun. 2016 Feb 9;7:10442. doi: 10.1038/ncomms10442.

33.

HER2 imaging in the ZEPHIR study.

Clark AS, DeMichele A, Mankoff D.

Ann Oncol. 2016 Apr;27(4):555-7. doi: 10.1093/annonc/mdw033. Epub 2016 Jan 22. No abstract available.

PMID:
26802154
34.

Neoadjuvant as Future for Drug Development in Breast Cancer--Response.

DeMichele A, Yee D, Paoloni M, Berry D, Esserman LJ; I-SPY2 Investigators.

Clin Cancer Res. 2016 Jan 1;22(1):269. doi: 10.1158/1078-0432.CCR-15-1643. No abstract available.

35.

Association of Depressed Anti-HER2 T-Helper Type 1 Response With Recurrence in Patients With Completely Treated HER2-Positive Breast Cancer: Role for Immune Monitoring.

Datta J, Fracol M, McMillan MT, Berk E, Xu S, Goodman N, Lewis DA, DeMichele A, Czerniecki BJ.

JAMA Oncol. 2016 Feb;2(2):242-6. doi: 10.1001/jamaoncol.2015.5482.

PMID:
26719971
36.

Palbociclib (PD0332991)-a Selective and Potent Cyclin-Dependent Kinase Inhibitor: A Review of Pharmacodynamics and Clinical Development.

Clark AS, Karasic TB, DeMichele A, Vaughn DJ, O'Hara M, Perini R, Zhang P, Lal P, Feldman M, Gallagher M, O'Dwyer PJ.

JAMA Oncol. 2016 Feb;2(2):253-60. doi: 10.1001/jamaoncol.2015.4701. Review.

PMID:
26633733
37.

Black breast cancer survivors experience greater upper extremity disability.

Dean LT, DeMichele A, LeBlanc M, Stephens-Shields A, Li SQ, Colameco C, Coursey M, Mao JJ.

Breast Cancer Res Treat. 2015 Nov;154(1):117-25. doi: 10.1007/s10549-015-3580-3. Epub 2015 Sep 29.

38.

Electroacupuncture Versus Gabapentin for Hot Flashes Among Breast Cancer Survivors: A Randomized Placebo-Controlled Trial.

Mao JJ, Bowman MA, Xie SX, Bruner D, DeMichele A, Farrar JT.

J Clin Oncol. 2015 Nov 1;33(31):3615-20. doi: 10.1200/JCO.2015.60.9412. Epub 2015 Aug 24.

39.

"Braking" the Cycle of Resistance in Endocrine Therapy for Breast Cancer.

DeMichele A, Chodosh LA.

Clin Cancer Res. 2015 Nov 15;21(22):4999-5001. doi: 10.1158/1078-0432.CCR-15-1146. Epub 2015 Jul 22.

40.

Association between self-report adherence measures and oestrogen suppression among breast cancer survivors on aromatase inhibitors.

Brier MJ, Chambless D, Gross R, Su HI, DeMichele A, Mao JJ.

Eur J Cancer. 2015 Sep;51(14):1890-6. doi: 10.1016/j.ejca.2015.06.113. Epub 2015 Jul 10.

PMID:
26169018
41.

Arthralgia among women taking aromatase inhibitors: is there a shared inflammatory mechanism with co-morbid fatigue and insomnia?

Bauml J, Chen L, Chen J, Boyer J, Kalos M, Li SQ, DeMichele A, Mao JJ.

Breast Cancer Res. 2015 Jun 28;17:89. doi: 10.1186/s13058-015-0599-7.

42.

Breast DCE-MRI Kinetic Heterogeneity Tumor Markers: Preliminary Associations With Neoadjuvant Chemotherapy Response.

Ashraf A, Gaonkar B, Mies C, DeMichele A, Rosen M, Davatzikos C, Kontos D.

Transl Oncol. 2015 Jun;8(3):154-62. doi: 10.1016/j.tranon.2015.03.005.

43.

Macroscopic optical physiological parameters correlate with microscopic proliferation and vessel area breast cancer signatures.

Chung SH, Feldman MD, Martinez D, Kim H, Putt ME, Busch DR, Tchou J, Czerniecki BJ, Schnall MD, Rosen MA, DeMichele A, Yodh AG, Choe R.

Breast Cancer Res. 2015 May 27;17:72. doi: 10.1186/s13058-015-0578-z.

44.

Anti-HER2 CD4(+) T-helper type 1 response is a novel immune correlate to pathologic response following neoadjuvant therapy in HER2-positive breast cancer.

Datta J, Berk E, Xu S, Fitzpatrick E, Rosemblit C, Lowenfeld L, Goodman N, Lewis DA, Zhang PJ, Fisher C, Roses RE, DeMichele A, Czerniecki BJ.

Breast Cancer Res. 2015 May 23;17:71. doi: 10.1186/s13058-015-0584-1.

45.

Neoadjuvant therapy for breast cancer: controversies in clinical trial design and standard of care.

White J, DeMichele A.

Am Soc Clin Oncol Educ Book. 2015:e17-23. doi: 10.14694/EdBook_AM.2015.35.e17.

46.

Evolving Information Needs among Colon, Breast, and Prostate Cancer Survivors: Results from a Longitudinal Mixed-Effects Analysis.

Tan AS, Nagler RH, Hornik RC, DeMichele A.

Cancer Epidemiol Biomarkers Prev. 2015 Jul;24(7):1071-8. doi: 10.1158/1055-9965.EPI-15-0041. Epub 2015 May 15.

47.

A hybrid effectiveness-implementation trial of an evidence-based exercise intervention for breast cancer survivors.

Beidas RS, Paciotti B, Barg F, Branas AR, Brown JC, Glanz K, DeMichele A, DiGiovanni L, Salvatore D, Schmitz KH.

J Natl Cancer Inst Monogr. 2014 Nov;2014(50):338-45. doi: 10.1093/jncimonographs/lgu033.

48.

Expectancy in real and sham electroacupuncture: does believing make it so?

Bauml J, Xie SX, Farrar JT, Bowman MA, Li SQ, Bruner D, DeMichele A, Mao JJ.

J Natl Cancer Inst Monogr. 2014 Nov;2014(50):302-7. doi: 10.1093/jncimonographs/lgu029.

49.

Safety and activity of alisertib, an investigational aurora kinase A inhibitor, in patients with breast cancer, small-cell lung cancer, non-small-cell lung cancer, head and neck squamous-cell carcinoma, and gastro-oesophageal adenocarcinoma: a five-arm phase 2 study.

Melichar B, Adenis A, Lockhart AC, Bennouna J, Dees EC, Kayaleh O, Obermannova R, DeMichele A, Zatloukal P, Zhang B, Ullmann CD, Schusterbauer C.

Lancet Oncol. 2015 Apr;16(4):395-405. doi: 10.1016/S1470-2045(15)70051-3. Epub 2015 Feb 27.

PMID:
25728526
50.

The Neoadjuvant Model Is Still the Future for Drug Development in Breast Cancer.

DeMichele A, Yee D, Berry DA, Albain KS, Benz CC, Boughey J, Buxton M, Chia SK, Chien AJ, Chui SY, Clark A, Edmiston K, Elias AD, Forero-Torres A, Haddad TC, Haley B, Haluska P, Hylton NM, Isaacs C, Kaplan H, Korde L, Leyland-Jones B, Liu MC, Melisko M, Minton SE, Moulder SL, Nanda R, Olopade OI, Paoloni M, Park JW, Parker BA, Perlmutter J, Petricoin EF, Rugo H, Symmans F, Tripathy D, van't Veer LJ, Viscusi RK, Wallace A, Wolf D, Yau C, Esserman LJ.

Clin Cancer Res. 2015 Jul 1;21(13):2911-5. doi: 10.1158/1078-0432.CCR-14-1760. Epub 2015 Feb 24.

Supplemental Content

Loading ...
Support Center